Cargando…

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

INTRODUCTION. On 4 and 5 November 2022, Madrid hosted the 15(th) edition of the Post-ECTRIMS Meeting, where neurologists specialised in multiple sclerosis (MS) outlined the most relevant novelties presented at the 2022 ECTRIMS Congress, held in Amsterdam from 26 to 28 October. AIM. To synthesise the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández, Óscar, Montalban, Xavier, Agüera, Eduardo, Aladro, Yolanda, Alonso, Ana, Arroyo, Rafael, Brieva, Luis, Calles, Carmen, Costa-Frossard, Lucienne, Eichau, Sara, García-Domínguez, José M., Hernández, Miguel Á., Landete, Lamberto, Llaneza, Miguel, Llufriu, Sara, Meca-Lallana, José E., Meca-Lallana, Virginia, Mongay-Ochoa, Neus, Moral, Ester, Oreja-Guevara, Celia, Ramió-Torrentà, Lluís, Téllez, Nieves, Romero-Pinel, Lucía, Rodríguez-Antigüedad, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	EVIDENZE 2023
Materias:	Revisión
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663806/ https://www.ncbi.nlm.nih.gov/pubmed/37365721 http://dx.doi.org/10.33588/rn.7701.2023167

Ejemplares similares

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
por: Fernández, Óscar, et al.
Publicado: (2023)

Cognitive Dysfunctions and Assessments in Multiple Sclerosis
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

ACTRIMS-ECTRIMS MSBoston 2014: Oral Presentations
Publicado: (2014)

ACTRIMS-ECTRIMS MSBoston 2014: Poster Sessions 2
Publicado: (2014)

Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014): Author Index
Publicado: (2014)

Commentary on the ECTRIMS–EAN guideline for pharmacological treatment of multiple sclerosis
por: Thompson, Alan J.
Publicado: (2018)

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014): Oral Presentations
Publicado: (2014)

ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Oral Presentations
Publicado: (2014)

ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Poster Session
Publicado: (2014)

Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?
por: Saposnik, Gustavo, et al.
Publicado: (2019)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
por: Otero-Romero, Susana, et al.
Publicado: (2023)

Empfehlungen zur COVID-19-Impfung bei MS -Positionspapier von ECTRIMS und EAN
por: Müller, Thomas
Publicado: (2021)

2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014) MS Journal Online: Poster Session 1
Publicado: (2014)

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
por: Lopez-Soley, Elisabet, et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
por: Sepúlveda, Maria, et al.
Publicado: (2016)

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
por: Meca-Lallana, José E., et al.
Publicado: (2021)

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
por: Meca-Lallana, Jose E, et al.
Publicado: (2021)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
por: Fernández-Velasco, José I., et al.
Publicado: (2022)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
por: Alonso Torres, A. M., et al.
Publicado: (2023)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
por: Aguirre, Clara, et al.
Publicado: (2020)

Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program?
por: Arriaza, María José, et al.
Publicado: (2022)

Cognitive impairment in multiple sclerosis: diagnosis and monitoring
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

[Novedades 1988]
por: Rodríguez Toro, Hero
Publicado: (1988)

Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5)
por: Meca-Lallana, Virginia, et al.
Publicado: (2019)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Novedades : Revista literaria y de información gráfica.
Publicado: (1911)

Cannot write session to /tmp/vufind_sessions/sess_l9br8np8hdfur29jglr105e4v0